Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.42 |
| ▸ | TXN | P10599 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441888 | 0.85 | MAPT (0.59) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL3754047 | 0.82 | MEN1 (0.56) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL444442 | 0.82 | KMT2A (0.56) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL1667688 | 0.82 | KMO (0.47) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL28374207 | 0.82 | KMO (0.41) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL210678 | 0.82 | MEN1 (0.66) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL16161191 | 0.82 | KMT2A (0.55) | MEN1KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL443863 | 0.81 | KIF11 (0.47) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL31390937 | 0.81 | MAPT (0.47) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL445042 | 0.81 | MEN1 (0.59) | MEN1KMT2ARAB9AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067457-A1 | HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-01-26 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11072611-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2021-07-27 | — | — | US | disclosed |
| CN-101014587-A | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORP (US) | 2007-08-08 | — | — | CN | disclosed |
| WO-2007016286-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| CN-1823057-A | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORP (US) | 2006-08-23 | — | — | CN | disclosed |
| EP-1601659-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-6440984-B1 | PROTECTION FOR GROWING AND HARVESTED CROPS; CONTROLLING TOBACCO BUDWORMS AND SOUTHERN ARMYWORMS; PESTICIDES; INSECTICIDES; MITICIDES; ANTHELMINTICS | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-27 | — | — | US | disclosed |
| US-6306866-B1 | 2-ALKOXY SUBSTITUTED PYRIMIDINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6153619-A | Aryl-substituted pyrimidines as insecticidal and acaricidal agents | AMERICAN CYANAMID COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072611-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | ENPP2, PRXL2A, TPX2 | MEN1 3182/4885KMT2A 1634/4885RAB9A 1501/4885 |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | DCK, DPYD, DTYMK | MEN1 4120/4885KMT2A 1988/4885RAB9A 4275/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | MEN1 1781/4885KMT2A 2942/4885RAB9A 490/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MEN1 1532/4885KMT2A 2721/4885RAB9A 699/4885 |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | MEN1 3384/4885KMT2A 1651/4885RAB9A 1170/4885 |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ADRB3, DRD3, OPRL1 | MEN1 4488/4885KMT2A 4190/4885RAB9A 3836/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MEN1 1532/4885KMT2A 2721/4885RAB9A 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.